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CHAPTER I
INTRODUCTION TO THE PROBLEM
As the fitness craze takes the world by stonn, people have come to realize that
muscle fatigue and soreness are common with progressive resistance exercise (PRE).
Many pharmaceutical companies have inferred that their drugs will relieve muscular
discomfort associated with exercise. One such drug is ibuprofen, (2-((4-isobutylphenyl)
propionic acid). This drug is a non-steroidal anti-inflammatory drug (NSAID), which is
also an analgesic and an antipyretic (Geisslinger and Dietzel, 1989). Claims, through
advertisements, suggest not only an analgesic effect, but also contend the drug may help
maintain regular training frequencies and intensities otherwise hindered by muscular
soreness and fatigue.
In the past, there was concern that the use ofNSAIDs with acute injuries or
muscular discomfort would interfere with the healing process. However, a recent
meta-analysis concluded that ibuprofen does not significantly delay healing and has
modest benefits over placebos for pain and soreness relief (Baumert, 1995; Forster,
Mager! and Beck, 1992). Ibuprofen relieves discomfort through the inhibition of
prostaglandin production (Nelson, Henderson, and Almekinders, 1993; Papazin, 1995),
the prevention of neutrophil activation, and stabilization of cellular lysosomal enzymes
(Cox, Gall, and Forbes, 1991). Surgical knee studies have shown that ibuprofen used
preoperatively and postoperatively lowers pain scores and aids in the rehabilitation
process (Forster et al., 1992; Nelson et al., 1993). Ingested ibuprofen takes 0.5 to 1.5
hours to reach the maximwn concentration in the body's plasma. Ibuprofen's efficacy is
four to six hours (Bawnert, 1995; Walker, Knihinicki, and Seideman, 1993). Food
ingestion with ibuprofen has not shown to significantly (p>0.05) increase the length of
time for maximal plasma concentration (Levine and Walker, 1992).
Anecdotal evidence exists suggesting that ibuprofen may positively affect
maximal strength output, presumably through an analgesic effect on the skeletal muscle
and joints. However, no current studies have investigated the effect of ibuprofen on
maximal voluntary strength. As the public continues searching for ergogenic aids to
enhance their physical perfonnance, the use of ibuprofen may be the answer for the day-
to-day discomfort associated with PRE.
Statement of the Problem
The problem of this study was to ascertain the effect of ibuprofen ingestion on
measured maximal voluntary strength output. The maximal voluntary strength output




The specific hypotheses were tested to analyze the effect of ibuprofen ingestion
upon maximal peak. torque and muscle endurance through isokinetic testing. The study
attempted to determine if the use of ibuprofen affects skeletal muscle maximum strength
output. The following hypotheses were tested at p>0.05:
HO l: There will be no significant difference between the placebo and ibuprofen
groups in the knee extension peak torque at an angular velocity of 60 degrees per second.
H02: There will be no significant difference between the placebo and ibuprofen
groups in the knee extension peak torque at an angular velocity of 180 degrees per
second.
H03: There will be no significant difference between the placebo and ibuprofen
groups in the knee extension peak torque at an angular velocity of 300 degrees per
second.
H04: There will be no significant difference between the placebo and ibuprofen
groups in the knee extension endurance torque between the first three repetitions and the




The study was delimited by the following:
1) The total number of subjects volunteering for the study was 17.
2) Testing was conducted on a Cybex II dynamometer with a Cybex data
reduction computer located in the Oklahoma State University Athletic Training Room.
3) There was one administration of 400 mg of ibuprofen to the subjects.
4) All subjects were highly trained athletes with greater than three years of
resistance training experience.
5) All subjects have no past history of medical difficulties with ibuprofen
ingestion.
6) All subjects were tested on their right leg.
Limitations
The study was limited by the following:
1) All subjects were required not to ingest ibuprofen for two weeks (14 days) prior
to testing.
2) All subjects were required not to resistance train the quadriceps muscle group
48 hours prior to each of three tests.
3) All subjects were required to produce a maximal effort at each of the three
levels of isokinetic knee extension testing.
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4) All subjects were to eat similar types and amounts offood prior to 400 mg of
ibuprofen or a placebo administration.
Assumptions
For the purposes of this study, the following assumptions were accepted by the
researcher:
1) Subjects gave a maximal effort on each repetition for each ofthe three levels.
2) Subjects were not informed if 400 mg of ibuprofen or a placebo was ingested.
3) Subjects returned 90 minutes after ingesting 400 mg of ibuprofen or a placebo
for testing.
4) Subjects abstained from quadriceps muscle group exercise for 48 hours prior to
each testing session.
Definitions
The following tenns are used in this study:
Computerized Isokinetic Testing Device = The machine that allows movement
through a set arc range of 90 degrees of knee flexion to 180 degrees of knee extension at
a set degree per second angular velocity.
Peak Torque = The highest value measured in foot per pounds by the computer as
the arm of isokinetic machine moves through the set arc range and set angular velocity.
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NSAIDs = Non-Steroidal Anti-inflammatory Drugs
18 = Ibuprofen, a non-steroidal anti-inflammatory drug that is the generic name of
Advil (Wyeth-Ayerst Pharmaceuticals).
Over-the-counter dosage = The amount of milligrams per pill or capsule that the
Federal Drug Administration allows to be sold without a prescription.
FDA = Federal Drug Administration is the government organization that controls
all facets of prescription and nonprescription drug use and availability.
Half-life = The length of time before a drug or chemical breaks down to half its
chemical properties in the nucleus.
Analgesic Effect = The anesthetizing of skeletal muscles by the drug ibuprofen.
PRE = Progressive Resistance Exercise with regard to weight lifting.
F3 = Mean of the first three repetitions at 300 degrees per second
L3 = Mean of the last three repetitions at 300 degrees per second
ROM = Range of Motion
ER = Endurance Ratio (L3/F3)
R(-) Enantiomer = The negative isomer ibuprofen becomes at the half-life of the
chemical breakdown and is unusable to the body.
S(+) Enantiomer = The positive isomer ibuprofen becomes at the half-life of the
chemical breakdown and is the isomer that carries the analgesic properties.
Albumin = A protein that accepts the ibuprofen, S(+) enantiomer, into the joint.
Hypokalemia = Extremely low levels of potassium in the blood manifested by
episodes of weakness or paralysis, tetany and postural hypotension.
Villus Hypotrophy = The reduction of multiple, minute projections of the
intestinal mucosa in the lumen of the small intestines.
Ulcer = A sore or a lesion that fonns in the lining of the stomach or duodenum
where pepsin and acid are present.
Duodenum = The upper 1/3 of the small intestinal tract.
Helicobacter pylori = The bacteria that destroy the mucosal lining of the stomach
increasing the possibility of an ulcer formation.
Strictures = A narrowing or constriction of the lumen tube, duct or hollow organ
such as the esophagus, ureter, or urethra.
Perforations = A small hole or fissure in the lining of the stomach or duodenum
lining.
Diarrhea = Frequent passage of unformed, watery, bowel movements. It is a






Most people in today' s exercise world are searching for ways to become bigger,
faster, and stronger. Injury, pain or muscular discomfort, before or during a workout can
interfere with one's effort to maximize exercise performance. These inconveniences send
a strong message to the pharmaceutical and nutritional supplement companies. One of
the most popular drugs advertised for the relief of exercise-induced muscular pain is
ibuprofen. Ibuprofen has been proven to eliminate muscle soreness, but its manufacturer
has claimed no ergogenic properties. These properties, along with anecdotal evidence,
are the basis upon which this investigation is based. For simplification, this chapter will
be divided into four sections:
1) Pharmacokinetics of Ibuprofen
2) Contraindications of Ibuprofen
3) Indications of Ibuprofen
4) Ibuprofen and Muscular Contractions
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Phannacokinetics of Ibuprofen
Ibuprofen, the generic form of Advil and Motrin, is a nonsteroidal
anti-inflammatory drug (NSAID). The most rapid form of ibuprofen absorption is via
oral ingestion (Schein, 1995). The onset of the anti-inflammatory and analgesic effect
begins in as little as 0.5 hours and reaches a maximwn plasma concentration in 1.8 ± .45
hours (Baumert, 1995; Walker, 1993). Additionally, in a study to investigate the
absorption rate of ibuprofen, 600 milligrams (mg) of ibuprofen was ingested with and
without the presence of food. The results indicated that there is not a significant (p>0.05)
difference in the amount of time required for maximal plasma concentration of ibuprofen
with or without the presence of food (Levine and Walker, 1992). Effectiveness of a
single dose, 400 mg of ibuprofen, is four to six hours (Baumert, 1995). A recent study
shows that 45% to 70% of a single dose is recovered in the urine 24 hours after ingestion
(Schein. 1995).
Ibuprofen breaks down in the gut following oral ingestion. The propionic acid
side-chain is transformed into the products hydroxyibuprofen and carboxyibuprofen in
the first 10.2 to 12.2 minutes. At 27.0 to 29.4 minutes after ingestion, the drug is
transformed into the plasma absorbable R(-) and S(+) enantiomers. The enantiomer R(-)
is inactive in humans, but the S(+) enantiomer contains the phannacological effects on
the body, (Gesslinger and Dietzel, 1989). The S(+) enantiomer is absorbed into the blood
plasma through the gut wall, (Levine and Walker, 1992). Although most of the S(+)
enantiomer is absorbed in the blood stream, the majority of its action takes place in the
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synovial joint; 60% of enantiomer binding occurs in the albumin of the joint (Cox et al.,
1991). Permeability of blood vessels and membranes allows the S(+) enantiomer to enter
the synovial joint (Rahim and Aubry, 1995; Walker, 1993), and the ibuprofen's anti-
inflammatory and analgesic properties take effect.
Contraindications of Ibuprofen
Side-effects are always possible with the use of any medication. Some side-
effects are predictable while others can cause unpredictable effects. In recent years,
patients, physicians, and scientists have recognized that frequent and long-term ibuprofen
use has led to numerous gastrointestinal disorders (Nelson and Henderson, 1993). Side-
effects are not limited solely to ibuprofen, but to all NSAIDs. Common NSAID
problems are: a bloated feeling, gas, heartburn, stomach pain, constipation, diarrhea,
nausea, vomiting, (Matsen, 1995), small intestinal disorders, and stomach ulcers, (Kwo
and Tremaine, 1995). The onset of documented gastrointestinal disorders dates from six
weeks to two years prior to manifestation of symptoms.
One study reported a 30% incidence of heartburn, gastric upset or headaches with
continuous NSAID use for 6 weeks, (Nelson and Henderson, 1993). In a controlled
clinical trial, the percentage of patients reporting one or more gastrointestinal complaints
ranged from 4% to 16% (Schein, 1995). A similar study revealed that 2% to 4% of
patients taking NSAIDs for one year had adverse gastrointestinal events (Graham, 1995).
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In one case, a 37-year-old woman was hospitalized for nausea, vomiting large volume
diarrhea, and hypokalemia. She reported taking 800 mg of ibuprofen three times a day
over a two year period for pelvic pain (Kwo and Tramaine, 1995). These studies
prompted physicians and drug companies to produce the following recommendations:
"NSAIDs should not be used routinely to treat pain without other signs or symptoms of
inflammation, since they are clearly associated with significant and occasionally serious,
adverse side-effects," (Baumert, 1995).
Ulceration is one of the most serious side-effects of prolonged ibuprofen use,
although it is not definitely known whether ibuprofen causes less peptic ulceration than
aspirin. A one-year study involving 885 patients, compared ibuprofen to aspirin. Upon
its conclusion, there were no reports of ibuprofen ulceration, while aspirin caused 13%
ulceration (p>.001), (Schein, 1995). Lesion formation results when an imbalance occurs
in the digestive fluids of the stomach and when the gastrointestinal tract is unable to
defend itself against the harsh effects caused by stomach acid and pepsin (Medical
Science Bulletin, 1995). Through the NSAID's inhibition of cyclooxgenase, 80% of
gastric lesions are formed, thereby terminating prostaglandin formation and diverting the
arachidonic acid metabolism to the lipoxygenase pathway (Kwo and Tremaine, 1995).
This disruption of prostaglandin production allows HeJicobacter pylori, (a bacteria), to
decay and destroy the mucosal lining of the stomach, rendering the stomach lining
susceptible to the damaging effects of acid and pepsin (Matsen, 1995; Medical Science
Bulletin, 1995). NSAIDs interfere with the body's bicarbonate production which
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nonnally neutralizes the stomach's naturally developed acids. Lack of bicarbonate can
also cause stomach ulcerations, (Medical Science Bulletin, 1995)
There is a direct correlation between the concentration ofNSAIDs and damage to
the small intestine (Medical Science Bulletin, 1995). Common problems are strictures,
ulcerations, perforations, diarrhea and villous atrophy. Patients who received NSAIDs
regularly for more than 6 months have an increased level of risk (14%), for developing
duodenal lesions (Kwo and Tremaine, 1995).
Indications of Ibuprofen
Ibuprofen is administered and recommended by physicians for treatment of
rheumatic disorders, osteoarthritis, fever and pain. Clinical studies with patients have
shown that ibuprofen reduces pain and inflammation better when compared to aspirin
(Schein, 1995; Gesslinger and Dietzel, 1989). The action site for many arthritic
conditions is the synovium. The S(+) enantiomer inhibits prostaglandin synthetase,
thereby causing the analgesic effect in the joint, (Romero and Rhodes, 1993; Cox et al.,
1991). Proper use of ibuprofen has been shown to reduce the body's naturally-fonning
arthritic condition, (Schein, 1995).
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Ibuprofen and Muscular Contractions
Weight training and conditioning programs are designed to develop muscle mass
and endurance by overloading the muscular contractions in a progressive resistance
exercise format. These muscular contractions cause inflanunation in and around the
muscle tissue which leads to muscular discomfort or delayed onset muscle soreness
(DOMS). There are two theories explaining this phenomenon, the tear theory and DOMS
theory.
The tear theory suggests that during exercise muscle tears occur in the individual
muscle fibers, (or sarcomere), from the concentric and especially eccentric muscular
contractions, (Saxton, Clarkson and James, 1995). These tears cause the inflammation
and pain in the joint. The DOMS theory suggests that the connective tissue in and around
the muscle is damaged by heavy muscular contractions, and that there is also a metabolic
imbalance of collagen surrounding the joint (Tuttle, 1995). Another study offers
evidence that neuromuscular function is impaired by eccentric muscle contractions. It is
hypothesized that the afferent receptors surrounding the skeletal muscle and connective
tissue recognize the inflammation which increases the muscular spasm and pain (Saxton
et al., 1995).
Documented studies indicate that ibuprofen reduces painful inflammation and
diminishes the sensitivity of the afferent receptors (Tuttle, 1995; Forster and Magerl,
1992). The properties of ibuprofen have led to its wide use for DOMS. These properties
suggest that ibuprofen can contribute positively to maximal voluntary strength output. If
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ibuprofen can affect the afferent receptors before exercise it is possible that muscular
discomfort would not be recognized by the central nervous system. This disruption may





Seventeen college age, male, varsity athletes, with consistent weight training
experience (> 3 years), were solicited for this investigation. All subjects were assumed to
be capable of eliciting a maximal force due to their extensive experience with progressive
resistance exercise (PRE). Individually, the subjects were questioned about their physical
fitness, PRE history, allergic reactions to ibuprofen, and were queried specifically about
any past medical history of gastrointestinal discomfort with ibuprofen use. The subjects
were also asked questions regarding their long-term use of ibuprofen or NSAIDs. An
oral briefing ofthe testing procedures and expected demand was given to each subject.
Following oral consent, the subjects agreed to sign an informed consent document
(Appendix A), as approved by the Oklahoma State University International Review
Board (lRB), (Appendix B).
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Preliminary Procedures
Prior to the pretest, each subject was requested to adhere to the following specific
guidelines: 1) The subjects were not to participate in weight training of the quadriceps
muscle group 48 hours prior to each of the three tests. 2) The subjects were not to ingest
any ibuprofen or NSAIDs 14 days prior to the pretest, because of a recommended
washout period, (Cox et al., 1991). 3) Subjects were required to arrive 1 1/2 hours (90
minutes) before each of the two posttest sessions for the double-blind random
administration of 400 mg of ibuprofen (Schein Pharmaceutical) or a placebo (lactose), as
prepared by a registered pharmacist. 4) After the 90 minute absorption period as
documented, the subjects were given the posttest.
Before the pretest, each subject was assigned a specific number to protect
confidentiality. Testing procedures were thoroughly outlined before each of the three
tests. The tester explained the instructions and defined the motivation for each subject
prior to each test. Each individual was given the same instructions. Subjects were
directed to exert a maximal effort/force with each repetition during each of the three
levels, (60 degrees/second, 180 degrees/second, and 300 degrees/second). The room was
kept quiet to minimize external interference.
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Procedures
The subjects were isokinetically tested for maximal peak torque at three
predetermined levels of velocity: 60 degrees/second (1.047 radians/second); 180
degrees/second (3.14 radians/second); 300 degrees/second (5.235 radians/second),
(Mognoni, Narici, Sirtori, 1994), on a Cybex II dynamometer interfaced with a Cybex
reduction computer. The experiment was structured utilizing isokinetic measurements
because it has proven to be a reliable tool for assessing muscular strength in orthopedic
and sport medicine settings, as well as providing test results which are both objective and
reproducible (Wilk and Romaniello, 1994). The acceleration period that occurs during an
isokinetic test affords valuable information on the neuromuscular maximal contraction,
(Chin and Su, 1994). Hasson reported that high speed concentric isokinetic exercise has a
significant impact on improving muscular torque production without deficits from
DOMS, (Weber and Servedio, 1994).
To ensure validity and reliability of the Cybex II isokinetic dynamometer, the
following variables were controlled during testing of each subject, (Ford, Bailey, Babich
and Worrell, 1994).
1) Fixed velocity of the Cybex n isokinetic dynamometer.
2) Body position with hip flexion and knee flexion standardized.
3) Contraction mode of the Cybex II was set in a fixed mode.
4) The gravity effect torque was standardized.
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The movement speed of the lever arm was set at a fixed speed (i.e. 60
degrees/second), and was used as the standard for all subjects. Even though strength
output may vary from subject to subject, the fixed velocity of the Cybex II isokinetic
device remains identical (Jacobson, Weber, Claypool and Hunt, 1992). The hips of each
subject were flexed at 110 degrees with knee flexion established at 90 degrees. This hip
and knee combination has been shown to create the best maximal peak torque during
quadriceps muscle group testing, (Ford et aI., 1994). The contraction mode on the Cybex
II was set for concentric muscle contraction as this is the common form of measurement
for maximal peak torque. Lastly, the gravity effect torque was standardized by placing
the axis of the Cybex II ann at the axis of the knee, and the lower leg pad 2.5 inches
superior to the medial malleolus (Chin and Su, 1994; Ford et al.). Subjects' positions
were stabilized by placement of four velcro straps, binding the tnmk, waist, hip, and
lower leg, while still allowing for full knee extension, since body movement has been
shown to interfere with the isokinetic values (Greenberger and Paterno, 1995; Magnoni et
aI., 1994).
Once the subjects were properly situated, the test began with two practice
contractions each at 25% of maximal contraction at each velocity level. These practice
contractions allowed the subject to realize the amount of force and speed that would be
expected during testing. The tests consisted of six repetitions at 60 degrees/second,
followed by six repetitions at 180 degrees/second and finally fifteen repetitions at 300
degrees/second. A two minute (120 seconds) rest period was given between each trial to
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minimize fatigue (Wilk and Ramanello, 1994). Total testing time was approximately 15
minutes.
Following the pretest on Monday, subjects were reminded to return 90 minutes
prior to their posttest on the next Wednesday. The following Friday, the subjects would
likewise return 90 minutes prior to the posttest. The 90 minute reappearance was to give
the subjects the ibuprofen or placebo for the required absorption period. All tests were
completed 48 hours apart. The.experimental procedures were identical for all tests.
The four variables that were measured during each isokinetic test were:
1) Maximal peak torque at 30 degrees/second or 1.047 radians/second
2) Maximal peak torque at 180 degrees/second or 3.14 radians/second
3) Maximal peak torque at 300 degrees/second or 5.235 radians/second
4) Endurance ratio at 300 degrees/second or 5.235 radians/second
The data was calculated in fooUpounds and appear in Appendix C.
Data Analysis
A paired t-test of means was used to compare 400 mg of ibuprofen and the
placebo group means for each of the dependent variables. The endurance ratio was
calculated by dividing the mean of the last three repetitions by the mean of the first three






Seventeen athletes participated in this investigation. One additional subject was
removed from the study, as he sustained a back injury while participating in an offseason
weight training and conditioning program. All subjects were pretested on a Monday. On
the following Wednesday, the random, double-blind administration of400 mg of
ibuprofen or a placebo was issued to the 16 participants remaining in the study. After a
90 minute absorption period, the subjects were tested again with the identical protocol
used for the pretest. On the following Friday, the other half of the double-blind study
was administered to the subjects. Once again, the same testing protocol was used on the
third day of testing. All subjects were in an offseason weight training program or
currently in season at the time of testing. Testing was completed during the same week




RAW SCORES MEASURED IN FOOT/POUNDS
subj PR60 PR180 PR300 PRF3 PRL3 PRER PL60 PL180 PL300 PLF3 PLL3 PLER 1860 18180 18300 IBF3 IBL3 IBER
1 190 132 72 56 62 1.11 192 148 108 102 88 0.86 214 156 116 112.7 86 0.76
2 218 172 134 126.6 85.3 0.61 194 186 130 98 97.3 0.99 208 180 152 145.3 100.7 0.69
3 190 140 86 47.3 78.7 1.67 214 188 126 111.3 92 0.83 196 172 128 115.3 84.7 0.73
--
4 250 194 156 136.7 84.7 0.62 240 192 156 144.7 84.7 0.59 192 188 144 104.7 103.3 0.73
5 222 168 108 89.3 79.3 0.89 224 166 122 100 77.3 0.77 204 168 120 112 84.3 0.75
6 78 72 60 51.6 47.3 0.92 100 84 68 63.3 51.3 0.81 84 80 66 46 44.7 0.97
7 145 95 62 62 43.6 0.7 162 105 72 70 39.3 0.56 144 104 72 69.3 42.7 0.62
8 144 132 120 113.3 99.3 0.88 144 150 136 126.7 116 0.92 126 166 134 121.3 112 0.92
9 185 132 94 88.6 72 0.81 166 130 98 92.3 72.7 0.79 158 124 102 98 69.3 0.71
10 216 150 108 106.6 93.3 0.88 208 154 122 106 103.3 0.96 194 150 130 114 100.7 0.68
11 196 144 110 108.7 84 0.77 140 156 134 114 112 0.98 166 166 132 116 106 0.9
12 222 128 96 78.3 84 1.07 Subject was dropped from the experiment because of a non-related back injury.
13 240 144 108 107.3 69.3 0.63 220 172 112 109.3 62 0.75 190 156 120 108.7 80 0.74
I-
14 168 108 72 71.3 45.7 0.64 144 124 94 83.3 63.3 0.76 154 114 90 86 67.3 0.78
I-
15 228 138 108 87.3 85 0.97 198 144 112 109.3 82 0.75 220 150 118 102.7 92 0.9
-
16 220 140 108 106.7 72 0.67 182 136 108 105 70 0.67 190 148 116 116 74.7 0.64
17 144 94 66 56 46.7 0.83 142 96 72 68 56.7 0.83 154 96 81 60.7 63.3 1.04
t-.J--
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Results at the Angular Velocity of 60 Degrees/Second
Statistical analysis for the maximal peak touque at 60 degrees/second found no
significant difference, (p < .05) between the ibuprofen and placebo groups (Table II).
However, there was statistical significance in the pretest and ibuprofen groups. The data
indicated a drop in the maximal peak torque in the ibuprofen when compared to the
placebo group. There was no statistical significance between the placebo and the pretest
groups. The first hypothesis was accepted as there was no significant difference between
the placebo and the ibuprofen groups in the knee extension maximal peak torque at an
angular velocity of 60 degrees/second. This lack of increase/decrease in maximal peak
torque rejected the investigator's theory, by anecdotal evidence, that ibuprofen may
increase voluntary maximal strength with the use of ibuprofen.
Results at the Angular Velocity of 180 Degrees/Second
Statistical analysis for the maximal peake torque at 180 degrees/second found no
significant difference, (p < .05) between the placebo and ibuprofen groups (Table II).
However, there were significant levels of improvement in the placebo and ibuprofen
groups when compared to the pretest group at this velocity. The second hypothesis was
accepted as there was no significant difference between the placebo and ibuprofen groups
in knee extension maximal peak torque at an angular velocity of 180 degrees/second.
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The lack of difference between the placebo and ibuprofen groups indicates that the use of
ibuprofen does not improve voluntary strength at 180 degrees/second.
Results at the Angular Velocity of 300 Degrees/Second
Statistical analysis for the maximal peak torque at 300 degrees/second found no
significant difference, (p < .05) between the placebo and ibuprofen groups (Table II).
However, there was significant improvement between the placebo and ibuprofen
compared to the pretest group. The third hypothesis was accepted as there was no
significant level of improvement between the placebo and ibuprofen groups at a maximal
peak torque at the angular velocity of 300 degrees/second. The lack of improvement
shows that ibuprofen results in no statistical benefit at an angular velocity of 300
degree/second.
Results of the Endurance Ratio at 300 Degrees/Second
Statistical analysis for the endurance ratio at 300 degrees/second found no
significant difference, (p < .05) between the pretest, placebo, and ibuprofen groups
(Table II). There was no significant improvement or decline in the endurance ratios. The
fourth hypothesis was accepted as there were no significant differences between the






Variable Number Mean Standard t value p >.05 2-tail
of cases Deviation probability
PL 60 179.375 38.552
16 0.89 .389
IB 60 174.625 36.432
PL 180 145.813 32.303
16 0.40 .691
IB 180 144.875 31.858
II
PL 300 110.625 24.998 I'
16 -1.70 .110 ~~
"




PL 60 = Placebo at 60 degrees/second IB 6Q = Ibuprofen at 60 degrees/second
PL 180 = Placebo at 180 degrees/second IB 18Q = Ibuprofen at 180 degrees/second
PL 3QO = Placebo at 300 degrees/second IB 300 = Ibuprofen at 300 degrees/second
PL ER = Placebo Endurance Ratio IB ER = Ibuprofen Endurance Ratio
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Discussion of Results
The results of the present experiment demonstrated no significant difference, (p <
.05) between the placebo and the ibuprofen groups, rejecting anecdotal evidence which
may lead one to speculate that ibuprofen improves maximal voluntary strength output.
Explanations concerning the lack of significance between the control and ibuprofen group
can only be speculative, although the following factors may be partly responsible for the
results:
1) Ibuprofen dosages were not administered according to body weight. Subjects'
weight ranged from 245 to 150 pounds, hence a difference in concentration may have
occurred.
2) The subjects were in a fatigued state as they were either in season or in off-
season conditioning/weight training. The pretest was conducted on Monday and may
have resulted in greater pretest scores as the weekend rest period seemed to be the reason
Friday's posttest scores were lower.
3) The subjects had a learned response with the usage of the Cybex II Isokinetic
Device.
4) The tainted nature of the subj ects precluded significant muscle soreness and
hence benefit from ibuprofen.
The subjects took 400 mg of ibuprofen, as is the FDA recommended over-the-
counter dosage. The FDA based these dosages on the average size of adults. An athlete,
in general, is different than the average adult in height, weight and body composition.
The body size of these athletes may demand higher dosages of ibuprofen for the afferent
,I
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receptor response at the neuromuscular junction. The increase of ibuprofen concentration
may positively affect a maximal voluntary strength output, by the inhibition of
prostaglandin production.
Another explanation may have been a fatigue factor. The subjects were W1der a
great amount of workload in their season or off-season training. This workload may have
placed too great a demand on the subjects throughout the week of testing. Fatigue was
very evident in the comparison between the subjects pretest on Monday and their posttest
on Wednesday and Friday. The mean peak torque at 60 degrees/second in the placebo
and ibuprofen groups decreased compared to the pretest group. Because the pretest
group was tested on Monday, the weekend allowed them to fully regain their energy and
recover strength. On Wednesday and Friday, the subjects had been through two or four
days of practice, off-season running, weight training. The off-season subjects were
beginning their second week of conditioning. The lack of time for the body to adjust to
the training demands could have also offset this group during the two posttests. The
other problem was that the subjects were required to arrive 90 minutes prior to post-
testing for the drug administration. This adjustment in an athlete's schedule can be very
difficult. The early arrival became a nuisance to many of the subjects which precluded a
poor effort during their test.
The final possible reason for the results may have resulted from an individual
learned response. Many of the subjects complained during the two posttests of the
increase in difficulty at the angular velocity of 60 degrees/second. Comments said were,
''This one is too hard," "I hate this level, you should have warned me on the difficulty,"
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and "You made this one harder this time versus the first time." The subj ects, regardless
of motivation, did not seem to exert the same maximal effort at this velocity as they did at
the pretest.
Additionally, many of the subjects realized after completing the pretest that 15
repetitions at 300 degrees/second is quite fatiguing. The load was not the problem: The
number of repititions was the common complaint. The subjects seemed to exert a lesser
force during the first few repititions so as not to struggle perfonning the last five
repetitions. This was apparent in many of the Cybex II output sheets. The effort of the
first three repetitions exhibited less foot/pounds than the middle five repetitions. The
repetitive scores tapered further for the last three repititions, as the leg began to fatigue.






SUMMARY, FINDINGS, CONCLUSIONS AND RECOMMENDAnONS
Sununary
The purpose of this study was to ascertain the effect of ibuprofen ingestion on
measured maximal voluntary strength output. seventeen athletes participated. One
subject was removed as he sustained a back injury. The subjects were isokinetically
tested for knee extension at three angular velocities, (60 degrees/second, 180
degrees/second, and 300 degrees/second). All subjects were pretested on Monday. On
the following Wednesday, the random, double-blind administration of 400 mg of
ibuprofen or a placebo was administered to the remaining sixteen subjects. After the 90
minute absorption period, the subjects were tested again with the identical protocol used
for the pretest. On the following Friday. the other half ofthe double-blind study was
administered to the subjects. Once again, the same testing protocol was used on the third





Statistical analyses of the investigation revealed the use of ibuprofen does not
significantly increase maximal voluntary strength output. At all levels (60
degrees/second, 180 degrees/second, and 300 degrees/second), the maximal peak torque
was unaffected by the oral ingestion of400 mg of ibuprofen. The data also indicated that
the endurance of maximal voluntary contractions at 300 degrees/second was not
significantly affected with the administration of ibuprofen.
HO1: There is no significant difference between the placebo and ibuprofen
groups in the knee extension maximal peak torque at an angular velocity of 60 degrees
per second. Accepted
H02: There is no significant difference between the placebo and ibuprofen
groups in the knee extension peak maximal peak torgue at an angular velocity of 180
degrees per second. Accepted
H03: There is no significant difference between the placebo and ibuprofen
groups in the knee extension maximal peak torque at an angular velocity of 300 degrees
per second. Accepted
H04: There is no significant difference between the placebo and ibuprofen
groups in the knee extension endurance ratio torque between the first three and last three
repetitions at an angular velocity of 300 degrees per second. Accepted
The original hypotheses were accepted as there was no significant difference, (p < .05)







The purpose of this study was to investigate the possibility that ibuprofen may
contain ergogenic properties by increasing maximal voluntary strength output. Although
this study indicated that there was no significant difference between ibuprofen or placebo
use on voluntary maximal strength output in leg extension, additional research with
ibuprofen is recommended as this experiment contained certain weaknesses.
Recommendations for Further Study
Although these weaknesses were only speculative, they are realistic regarding the
data collected. Future investigations into the use of ibuprofen and resistant training
should include all or some of the following changes:
1) Athletes should not be in season or in an off-season conditioning program and
should be idle during the week of testing.
2) The ibuprofen should be administered in higher dosages accordingly, as the
subjects' body weight may be a factor.
3) The use of multiple practice sessions on the isokinetic device prior to testing to
eliminate a possible learned response.
The literature review and anecdotal evidence indicate too many positive responses to not
continue with further studies.
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"I hereby authorize or direct Dr. Jacobson, Dr. Edwards.
Dr. Kulling and Wade Bartlett, or assistants, or associates to perform the following
treatment or procedure."
Initiate a knee extension strength measurement on isokinetic machine. The subjects will
perform 6 repetitions at 60 degrees/second, 6 repetitions at 180 degrees/second, 15
repetitions at 300 degrees/second. The subject will be given a 2 minute (120 second) rest
period between each level of testing.
The subjects will be administered 400 mg of ibuprofen or a placebo. A double-blind
randomized design will be used to administer either a placebo or ibuprofen. The subject
will return to the testing site 1 1/2 hr (90 minutes) following ingestion to perform the test
again using the same protocol as the pre-test.
The procedure will last approximately 15 minutes per testing session. All data will be
kept confidential.
You, the subject, may experience some discomfort in your quadricep muscle group as a
result of the isokinetic test, however this wiH not be unlike what you may have
experience during a normal bout of weight training. Although highly unlikely, you may
also experience some gastric discomfort from the administration of the placebo or
ibuprofen, but this will not last long or cause any permanent damage. Possible benefits
from this study will include, but not be limited to, rejecting or accepting the hypothesis
that ibuprofen can be beneficial to maximum strength output.
This is done as part of an investigation entitled, "The effect of Ibuprofen on Measurement
of Maximal Voluntary Strength."
The purpose of this investigation is to ascertain the physiological benefits, if any, of the
use of ibuprofen on strength performance.
I understand that participation is voluntary, there is no penalty for refusal to participate,
and that I am free to withdraw my consent and participation in this project at anytime
without penalty after notifying the project director.
I may contact Dr. Bert Jacobson at (405) 744-5500 or Wade Bartlett at (405) 744-7416.
I may also contact Gay Clarkson, Executive Secretary, 305 Whitehurst, Oklahoma State
University, Stillwater, Oklahoma, 74078, (405) 744-5700.
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I have read and fully understand the consent fonn. I sign it freely and voluntarily. A







I certify that I have personally explained all elements of this form to the subject or his
representative before requesting the subject or his representative to sign it.
Signed: _
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